Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 18;13(1):1849–1867. doi: 10.1080/21505594.2022.2136433

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 9. — The influence of inhibitors sunitinib and erlotinib on NDV F, AP1M1, and AP2M1 protein expression. (a and b) Viral F mRNA expression of cells infected with an NDV containing a wildtype (rSG10*) or mutated (rSG10*-F/Y524A, rSG10*-F/Y527A, or rSG10*-F/Y524AY527A) YLMY motif and treated with sunitinib (a) or erlotinib (b). The cells were infected with NDV at 37 ℃ for 1 h, and then the cells were treated with 1 µm sunitinib or 10 µm erlotinib; DMSO was used as a negative control. The p-values were calculated by a two-way ANOVA; *p <0.05; **p <0.01; ***p <0.001; n = 3. (c and d) the F, AP1M1, and AP2M1 protein expression at 24 hpi (c) or 36 hpi (d) in cells infected with an NDV containing a wildtype (rSG10*) or mutated (rSG10*-F/Y524A, rSG10*-F/Y527A, or rSG10*-F/Y524AY527A) YLMY motif and treated with sunitinib or erlotinib. (e) Quantitative analysis of the viral F and host AP1M1 and AP2M1 protein expression by treatment group (sunitinib, erlotinib, or DMSO). (f) Quantitative analysis of the viral F and host AP1M1 and AP2M1 protein expression by NDV strain (rSG10*, rSG10*-F/Y524A, rSG10*-F/Y527A, or rSG10*-F/Y524AY527A). (g) Virus titre of each treatment group (sunitinib, erlotinib, or DMSO). The virus titer was measured as the tissue culture infective dose by inoculating naive cells with supernatants from infected cells. (h) Virus titer of each NDV strain (rSG10*, rSG10*-F/Y524A, rSG10*-F/Y527A, or rSG10*-F/Y524AY527A). The p-values were calculated by a two-way ANOVA; *p <0.05; **p <0.01; ***p <0.001; n = 3.